Overview

Phase I Pharmacokinetic Study (SALBLOCK)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the extent to which the charcoal prevents the absorption of salmeterol and fluticasone via the GI tract. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve (AUCt).
Phase:
Phase 1
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Charcoal
Fluticasone
Salmeterol Xinafoate
Xhance